amodiaquine

Trade name: camoquin

Small moleculeapproved

Amodiaquine is a medication used to treat malaria, including Plasmodium falciparum malaria when uncomplicated. The mechanism of plasmodicidal action of amodiaquine is not completely certain. Like other quinoline derivatives, it is thought to inhibit heme polymerase activity. This results in accumulation of free heme, which is toxic to the parasites. The drug binds the free heme preventing the parasite from converting it to a form less toxic. This drug-heme complex is toxic and disrupts membrane function. The side effects of amodiaquine are generally minor to moderate and are similar to those of chloroquine. Rarely liver problems or low blood cell levels may occur. When taken in excess headaches, trouble seeing, seizures, and cardiac arrest may occur. After oral administration amodiaquine hydrochloride is rapidly absorbed,and undergoes rapid and extensive metabolism to desethylamodiaquine which concentrates in red blood cells. It is likely that desethylamodiaquine, not amodiaquine, is responsible for most of the observed antimalarial activity, and that the toxic effects of amodiaquine after oral administration may in part be due to desethylamodiaquine. — NCATS

Clinical trial activity

121 trials · 144 clinical orgs · 1 marketing orgs

Phase 1
9
Phase 2
47
Phase 3
39
Phase 4
48

Earliest trial started Mar 1, 2001 (NCT00137514)

Timeline

1950s

  1. Jun 1, 1950

    Parke-Davis — First NDA Organization

  2. Jun 1, 1950

    Parke-Davis — NDA Organization

2000s

  1. Jan 1, 2001

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2003

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Mechanism of action

Approval history

  • approved

Chemistry & pharmacology

Loading structure…

SMILES

CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
Mol. weight
355.87 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Discontinued

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • amiodiaquine
  • amodiaquin
  • amodiaquina
  • amodiaquina
  • amodiaquin dihydrochloride
  • amodiaquin dihydrochloride dihydrate
  • amodiaquine
  • amodiaquine
  • amodiaquine
  • amodiaquine
  • amodiaquine
  • amodiaquine
  • amodiaquine
  • amodiaquine
  • amodiaquine
  • amodiaquine
  • amodiaquine hcl
  • amodiaquine hcl
  • amodiaquine hcl
  • amodiaquine hydrochloride
  • amodiaquine hydrochloride
  • amodiaquine hydrochloride
  • amodiaquine hydrochloride
  • amodiaquinum
  • amodiaquinum
  • camochin
  • camoquin
  • camoquin
  • camoquin
  • camoquin
  • camoquin
  • camoquinal
  • camoquine
  • camoquin hcl
  • camoquin hcl
  • camoquin hcl
  • camoquin hydrochloride
  • flavoquine
  • flavoquine
  • flavoquine
  • gnf-pf-5648
  • gnf-pf-5648
  • sj000110703
  • sj000110703
  • sunoquine
  • tcmdc-123932
  • tcmdc-123932

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06967519Phase 4Dec 31, 2025National Institutes of Health (NIH), Yale University
NCT06083688Phase 4Oct 31, 2024Kamuzu University of Health Sciences, University of Liverpool
NCT06182176N/AMay 27, 2024Kintampo Health Research Centre, Ghana, University of London
NCT06173206Phase 3Mar 15, 2024University of London
NCT05951595Phase 3Jan 1, 2024Mahidol University, University of Oxford
NCT05946642Phase 3Jul 15, 2023Malaria Consortium
NCT06076213Phase 4May 1, 2023Centers for Disease Control and Prevention (CDC), Global Health Innovative Technology Fund, Government of the Democratic Republic of the Congo
NCT05764746Phase 2/Phase 3 (Phase 3)Apr 1, 2023Muhimbili University, The Swedish Research Council, Uppsala University
NCT05550909Phase 2Oct 17, 2022Malaria Research and Training Center, Bamako, Mali, University of London
NCT06300970Phase 4Aug 9, 2022Centers for Disease Control and Prevention (CDC), Government of Liberia
NCT05471544Phase 3Jul 18, 2022Malaria Consortium
NCT05478954Phase 4Jul 15, 2022Malaria Consortium
NCT05354258N/AJun 16, 2022University of London
NCT05323721Phase 4Jun 1, 2022Government of Uganda, Malaria Consortium
NCT05343312Phase 4Mar 16, 2022United States Agency for International Development
NCT05081089Phase 2Oct 12, 2021Malaria Research and Training Center, Bamako, Mali, University of London
NCT04816461Phase 4Jul 31, 2021Institut et Haute école de la Santé, La Source
NCT04829695Phase 4Apr 5, 2021Association Camerounaise pour le Marketing Social (ACMS), Cameroon, Government of Cameroon, Impact Malaria, Cameroon, University of Yaounde
NCT04618523Phase 4Oct 26, 2020Government of Congo, Government of the Democratic Republic of the Congo, University of Kinshasa, World Health Organization
NCT04532931Phase 2Sep 3, 2020Medicines for Malaria Venture, Shin Poong Pharmaceuticals
Showing 20 of 121 trials
Page 1 / 7

Organizations

Research & Development (144)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of LondonAcademic/Hospital363242001
Centers for Disease Control and Prevention (CDC)Government9822004
Malaria Research and Training Center, Bamako, MaliAcademic/Hospital8032005
SanofiFor profit8842005
University of OxfordAcademic/Hospital8742008
Centre MurazAcademic/Hospital7422007
Institute of Tropical Medicine, BelgiumAcademic/Hospital7222007
Cheikh Anta Diop University, SenegalAcademic/Hospital6142004
Kwame Nkrumah University of Science and TechnologyAcademic/Hospital6222006
Medical Research CouncilGovernment6032003
Institut et Haute école de la Santé, La SourceAcademic/Hospital5122012
Mahidol UniversityAcademic/Hospital5042008
University of CopenhagenAcademic/Hospital5032003
University of HeidelbergAcademic/Hospital5412005
University of YaoundeAcademic/Hospital5322003
World Health OrganizationGovernment5022001
Bill and Melinda Gates FoundationAcademic/Hospital4132004
Government of FranceGovernment4132004
Karolinska InstituteAcademic/Hospital4412002
Malaria ConsortiumAcademic/Hospital4422022
144 organizations
Page 1 / 8

Marketing (1)

OrganizationOrg typeRelationshipDate
Parke-DavisFor profitNDAJun 1, 1950